ATI RN
ATI Pathophysiology Final Exam
1. A hospital patient's complex medical history includes a recent diagnosis of kidney cancer. Which of the following medications is used to treat metastatic kidney cancer?
- A. Filgrastim (Neupogen)
- B. Aldesleukin (Proleukin)
- C. Interferon alfa-2b (Intron A)
- D. Darbepoetin alfa (Aranesp)
Correct answer: B
Rationale: The correct answer is B: Aldesleukin (Proleukin). Aldesleukin is a medication used in the treatment of metastatic kidney cancer. It is a recombinant interleukin-2 that works by stimulating the immune system to attack cancer cells. Choice A, Filgrastim, is a medication used to stimulate the production of white blood cells. Choice C, Interferon alfa-2b, is used in the treatment of certain cancers but not specifically metastatic kidney cancer. Choice D, Darbepoetin alfa, is used to treat anemia by stimulating red blood cell production and is not indicated for metastatic kidney cancer.
2. Why is it important for a patient to take a new oral contraceptive at the same time each day?
- A. Taking the medication at the same time each day helps maintain stable hormone levels, which is critical for preventing pregnancy.
- B. Taking the medication at the same time each day reduces the risk of breakthrough bleeding.
- C. Taking the medication at the same time each day ensures consistent absorption and effectiveness.
- D. Taking the medication at the same time each day is important, but missing a dose occasionally is not a concern.
Correct answer: A
Rationale: The correct answer is A. Taking oral contraceptives at the same time each day is crucial for maintaining stable hormone levels, which is essential for the contraceptive's effectiveness in preventing pregnancy. Choice B is incorrect because the primary reason for taking the medication consistently is hormone level stability, not specifically to reduce breakthrough bleeding. Choice C is incorrect as it focuses on absorption and effectiveness, which are important but do not address the main reason for consistent timing. Choice D is incorrect because missing doses can impact contraceptive efficacy, making consistent timing essential for optimal protection.
3. A patient has been prescribed conjugated estrogens for the treatment of menopausal symptoms. What should the nurse include in the patient teaching?
- A. Increase the intake of calcium-rich foods.
- B. Decrease the intake of high-fat foods.
- C. Avoid the use of tobacco.
- D. Avoid exposure to sunlight.
Correct answer: A
Rationale: The correct answer is A: Increase the intake of calcium-rich foods. Patients taking conjugated estrogens should increase their intake of calcium-rich foods to help prevent osteoporosis. Estrogen therapy can lead to an increased risk of osteoporosis, so ensuring an adequate intake of calcium is crucial. Choices B, decreasing high-fat foods, and C, avoiding tobacco, are general health recommendations but not directly related to the prescription of conjugated estrogens. Choice D, avoiding exposure to sunlight, is not a direct concern when taking conjugated estrogens.
4. The signs of thyroid crisis resulting from Graves' disease include:
- A. constipation with gastric distension.
- B. bradycardia and bradypnea.
- C. hyperthermia and tachycardia.
- D. constipation and lethargy.
Correct answer: C
Rationale: Thyroid crisis in Graves' disease typically presents with hyperthermia (high body temperature) and tachycardia (rapid heart rate). These symptoms are a result of excessive thyroid hormone production and can lead to life-threatening complications if not promptly addressed. Choices A, B, and D are incorrect because constipation with gastric distension, bradycardia and bradypnea, and constipation and lethargy are not typical signs of a thyroid crisis in Graves' disease.
5. In a patient with chronic kidney disease and a hemoglobin level of 9 g/dL, which of the following treatments is most appropriate?
- A. Iron supplementation
- B. Erythropoiesis-stimulating agents
- C. Blood transfusion
- D. Vitamin B12 supplementation
Correct answer: B
Rationale: In chronic kidney disease, anemia commonly occurs due to decreased erythropoietin production. Erythropoiesis-stimulating agents, such as erythropoietin or darbepoetin, are the mainstay of treatment to stimulate red blood cell production. Iron supplementation is more appropriate for iron-deficiency anemia, not the anemia of chronic kidney disease. Blood transfusion is reserved for severe cases or acute blood loss. Vitamin B12 supplementation is indicated for megaloblastic anemia caused by vitamin B12 deficiency, not specifically in chronic kidney disease-related anemia.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access